These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 27070994

  • 21. The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease.
    Chang LS, Lo MH, Li SC, Yang MY, Hsieh KS, Kuo HC.
    Oncotarget; 2017 Jan 10; 8(2):2044-2052. PubMed ID: 27893416
    [Abstract] [Full Text] [Related]

  • 22. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
    Iwashima S, Kimura M, Ishikawa T, Ohzeki T.
    Clin Drug Investig; 2011 Jan 10; 31(3):191-9. PubMed ID: 21456105
    [Abstract] [Full Text] [Related]

  • 23. Predictive Value of Serum Lipid for Intravenous Immunoglobulin Resistance and Coronary Artery Lesion in Kawasaki Disease.
    Shao S, Zhou K, Liu X, Liu L, Wu M, Deng Y, Duan H, Li Y, Hua Y, Wang C.
    J Clin Endocrinol Metab; 2021 Sep 27; 106(10):e4210-e4220. PubMed ID: 33837779
    [Abstract] [Full Text] [Related]

  • 24. Difference in Risk Factors for Subtypes of Acute Cardiac Lesions Resulting from Kawasaki Disease.
    Yamashita M, Ae R, Yashiro M, Aoyama Y, Sano T, Makino N, Nakamura Y.
    Pediatr Cardiol; 2017 Feb 27; 38(2):375-380. PubMed ID: 27878631
    [Abstract] [Full Text] [Related]

  • 25. Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial.
    Lin SY, He L, Xie LP, Wang Y, Lin YX, Cao YY, Yan WL, Liu F, Huang GY.
    Trials; 2021 Dec 11; 22(1):898. PubMed ID: 34895290
    [Abstract] [Full Text] [Related]

  • 26. Corticosteroid Therapy Might be Associated with the Development of Coronary Aneurysm in Children with Kawasaki Disease.
    Zhao CN, Du ZD, Gao LL.
    Chin Med J (Engl); 2016 Apr 20; 129(8):922-8. PubMed ID: 27064036
    [Abstract] [Full Text] [Related]

  • 27. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb 20; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 28. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
    Masuzawa Y, Mori M, Hara T, Inaba A, Oba MS, Yokota S.
    Ther Apher Dial; 2015 Apr 20; 19(2):171-7. PubMed ID: 25257673
    [Abstract] [Full Text] [Related]

  • 29. [Clinical analysis of 942 cases of Kawasaki disease].
    Zhang W, Li Q, Zhao XD, Tang XM, Wang XG, Wang M, Wu DQ, Ou Q, Yang XQ.
    Zhonghua Er Ke Za Zhi; 2006 May 20; 44(5):324-8. PubMed ID: 16780705
    [Abstract] [Full Text] [Related]

  • 30. Z-score is a possible predictor of the risk of coronary artery lesion development in patients with Kawasaki disease in Japan.
    Suzuki T, Kakimoto N, Tsuchihashi T, Suenaga T, Takeuchi T, Shibuta S, Kitano N, Suzuki H.
    Eur J Pediatr; 2021 Sep 20; 180(9):2797-2805. PubMed ID: 33763715
    [Abstract] [Full Text] [Related]

  • 31. [Risk factors for coronary artery lesions in children with Kawasaki disease].
    Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec 20; 14(12):938-41. PubMed ID: 23234782
    [Abstract] [Full Text] [Related]

  • 32. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
    Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, Morikawa A.
    J Pediatr; 2006 Sep 20; 149(3):336-341. PubMed ID: 16939743
    [Abstract] [Full Text] [Related]

  • 33. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, Mossberg M, Kucera F, Tulloh R, Standing JF, Swallow V, McCormack R, Herberg J, Levin M, Wan M, Klein N, Connon R, Walker AS, Brogan P.
    Trials; 2023 Jan 26; 24(1):60. PubMed ID: 36703139
    [Abstract] [Full Text] [Related]

  • 34. The effects of early intravenous immunoglobulin therapy for Kawasaki disease: The 22nd nationwide survey in Japan.
    Kuwabara M, Yashiro M, Ae R, Yanagawa H, Nakamura Y.
    Int J Cardiol; 2018 Oct 15; 269():334-338. PubMed ID: 30049499
    [Abstract] [Full Text] [Related]

  • 35. Assessment of risk factors for Korean children with Kawasaki disease.
    Kim JJ, Hong YM, Yun SW, Han MK, Lee KY, Song MS, Lee HD, Kim DS, Sohn S, Ha KS, Hong SJ, Kim KJ, Park IS, Jang GY, Lee JK, Korean Kawasaki Disease Genetics Consortium.
    Pediatr Cardiol; 2012 Apr 15; 33(4):513-20. PubMed ID: 22105492
    [Abstract] [Full Text] [Related]

  • 36. Neutropenia after intravenous immunoglobulin therapy is associated with coronary artery lesions in children with Kawasaki disease: a case control study.
    Wang Z, Weng F, Li C, Shi H, Tang Z, Qiu H, He Y, Wu R, Chu M.
    BMC Pediatr; 2018 Feb 21; 18(1):76. PubMed ID: 29466965
    [Abstract] [Full Text] [Related]

  • 37. Predictive value of monocyte to HDL-C ratio for coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
    Wang JR, Zhao HZ, Chang LJ, Xu X, Gao Y, Li M, Kong QY, Wang MM, Zhao CF.
    Eur J Pediatr; 2023 Oct 21; 182(10):4399-4406. PubMed ID: 37480545
    [Abstract] [Full Text] [Related]

  • 38. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM, Shulman ST.
    J Clin Pharm Ther; 2015 Dec 21; 40(6):620-5. PubMed ID: 26547265
    [Abstract] [Full Text] [Related]

  • 39. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
    Qin L, Saumu MT, Wang H, Shi H, Hu X, Cheng P.
    J Huazhong Univ Sci Technolog Med Sci; 2005 Dec 21; 25(3):348-50, 370. PubMed ID: 16201293
    [Abstract] [Full Text] [Related]

  • 40. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
    PLoS One; 2015 Dec 21; 10(12):e0144603. PubMed ID: 26658843
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.